The Arrival of Novel Agent Classes in B-Cell Non-Hodgkin Lymphoma: A Personal Guide to Integrating New Therapy Into Patient Care

The Arrival of Novel Agent Classes in B-Cell Non-Hodgkin Lymphoma: A Personal Guide to Integrating New Therapy Into Patient Care is organized by PeerView Institute for Medical Education (PVI), Penn State College of Medicine and will be held from Jul 05, 2018 - Jul 04, 2019.

Target Audience:
This activity has been designed to meet the educational needs of medical oncologists, hematologist-oncologists, and other clinicians involved in the management of patients with B-cell lymphoma

Accreditation:
Providership, Credit, and Support:
The Penn State College of Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Description and Educational Objectives:
In this activity, which is based on a recent live symposium held at the 2018 American Society of Clinical Oncology Annual Meeting (ASCO 2018), a panel of leading clinicians offers thought-provoking perspectives on the science that has validated newer agent classes in B-cell lymphoma, including therapies such as BTK and PI3K inhibitors, immunomodulators, next-generation antibodies, CAR-T therapy, and other options. The panel also shares insights from their own practice on how best to bridge the divide between clinical research and daily care, focusing on issues such as therapeutic sequencing, awareness and management of adverse events that may limit the benefit of treatment, appropriate dosing in different malignant settings, and the clinical potential of novel strategies, including newer combination approaches, across a range of indolent and aggressive B-cell malignancies.

Upon completion of this activity, participants should be better able to:
• Summarize updated evidence about novel agent classes in B-cell non-Hodgkin lymphoma, including B-cell receptor inhibitors, apoptosis agents, next-generation antibodies, immunomodulators, and other emerging strategies
• Discuss patient and prognostic factors that may be used to personalize treatment with newer agent classes in B-cell non-Hodgkin lymphoma
• Recommend therapy with novel agents for newly diagnosed or relapsed/refractory B-cell non-Hodgkin lymphoma, including in the context of a clinical trial
Manage adverse events related to treatment with newer agents in patients with B-cell non-Hodgkin lymphoma

Additional details will be posted as soon as they are available.